Sildenafil sublingual - iX Biopharma

Drug Profile

Sildenafil sublingual - iX Biopharma

Alternative Names: PheoniX™; Sildenafil citrate - iX Biopharma; Sildenafil wafer - iX Biopharma

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator iX Biopharma
  • Class Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Erectile dysfunction

Most Recent Events

  • 01 Jul 2016 Phase-III clinical trials in Erectile dysfunction (In volunteers) in Australia (Sublingual) (NCT02850718)
  • 09 Jun 2016 iX Biopharma has patent protection for WaferiX™ drug delivery technology in South Korea, Japan, Indonesia, Singapore, Australia, New Zealand and Malaysia ,,
  • 09 Jun 2016 iX Biopharma has patents pending for WaferiX™ drug delivery technology in USA, Europe, China, India, Canada, South Africa, Hong Kong, Thailand and Vietnam ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top